Primary systemic therapy (PST) of locally advanced breast cancer using doxorubicin/docetaxel combination

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2879-2880

  Dank, Magdolna ^a   Zergenyi, E ^a   Domotori, Zs ^a   Lahm, E ^a   Kulka, J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Breast cancer; Doxorubicin Docetaxel; Electrocardiogram (ECG); Oestrogen receptor status (ER status); Pathological complete response (pCR); Primary systemic therapy; Primary systemic therapy (PST); Progesterone receptor status (PR status)

Indexed keywords

DOCETAXEL; DOXORUBICIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECORDING; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TOXICITY; TUMOR BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM STAGING; PACLITAXEL; TAXOIDS;

EID: 0043125528     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Green MC and Hortobagyi GN: Neoadjuvant chemotherapy for perable breast cancer. Oncology (Huntington) 16(7):871-84, 889; discussion 889-90, 892-4, 897-8, 2002.
2. Esteva FJ and Hortobagyi GN: Integration of systemic chemotherapy in the management of primary breast cancer. The Oncologist 3: 300-313, 1998.
3. Heikki Joensuu: Treatment of locally advanced and metastatic breast cancer In: Oxford Textbook of Oncology (Souhami RL, Tannock I, Hohenberger P and Horiot J-C, eds) NewYork, Oxford University Press 2002 pp 1763-1786.
4. Smith IC, Heys SD and Hutcheon AW: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-66, 2002.
5. Ferreira Filho AF, Crown J et al: 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. Anticancer Res 22: 2471-2471, 2002.
6. De Rosa L and Lalle M: Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer. Anticancer Res 21(2B) 1367-1370, 2001.
7. Cardoso F and Ferreira Filho AF: Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breat cancer: results of feasibility study. Anticancer Res21(1B):789-795, 2001.
8. Egewa T and Kubota T: Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner. Anticancer Res 21(4A):2597-25600, 2001.
9. Miller AB, Hoogstraten B and Staquet M: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
10. Gradishar WJ: Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer. Clin Breast Cancer 2: S1:31-35, 2001.
11. Aapro M: Neoadjuvant therapy in breast cancer: Can we define its role? The Oncologist 6: S3:36-39, 2001.